📊 BOLT Key Takeaways
Is Bolt Biotherapeutics, Inc. (BOLT) a Good Investment?
Bolt Biotherapeutics is a pre-revenue biotech company with $26K in annual revenue, burning $8M in operating cash flow annually against only $11.6M in cash reserves—implying ~1.4 years of runway at current burn rate. Without demonstrated commercial products or significant revenue, the company faces critical funding risk and lacks fundamental operational viability in its current form.
Bolt Biotherapeutics shows very weak fundamentals, with minimal revenue growth, deeply negative operating and net margins, and substantial ongoing cash burn. While the balance sheet has no meaningful debt and short-term liquidity ratios appear solid, the current cash position looks thin relative to annual operating outflows, making funding risk a central concern. Growth quality is poor because revenue has not scaled enough to offset R&D and operating costs.
Bolt Biotherapeutics, Inc. Key Strengths (BOLT)
- Zero debt structure provides financial flexibility and eliminates interest burden
- Strong current ratio of 3.51x indicates adequate short-term liquidity to meet obligations
- Minimal capital expenditure of $72K demonstrates lean operational footprint
- Debt-free balance sheet reduces financial leverage risk
- Current and quick ratios of 3.59x indicate adequate near-term balance sheet liquidity
- Positive reported revenue base provides some non-zero operating inflow
BOLT Stock Risks: Bolt Biotherapeutics, Inc. Investment Risks
- Near-zero revenue of $26K provides no commercial validation or cash generation
- Operating cash burn of $8M annually against $11.6M cash reserves creates critical funding timeline
- Massive operating losses with -29,234.6% operating margin indicate unsustainable business model
- Limited cash runway (~1.4 years) without external funding or revenue inflection
- Zero Form 4 insider filings in 90 days suggests no management confidence demonstrated through transactions
- Operating loss of $36.11M on just $7.70M of revenue reflects an unsustainable cost structure
- Free cash flow of -$39.92M versus $11.70M of cash suggests limited runway without additional capital
- Flat revenue growth indicates weak commercial traction or limited monetization progress
Key Metrics to Watch
- Cash burn rate and months of cash runway remaining
- Revenue growth rate and timing of product commercialization
- Operating cash flow trajectory and path to cash flow breakeven
- Quarterly operating cash burn relative to cash and equivalents
- Revenue growth and operating loss improvement
Bolt Biotherapeutics, Inc. (BOLT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.51x current ratio provides a solid financial cushion.
BOLT Profit Margin, ROE & Profitability Analysis
BOLT vs Healthcare Sector: How Bolt Biotherapeutics, Inc. Compares
How Bolt Biotherapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bolt Biotherapeutics, Inc. Stock Overvalued? BOLT Valuation Analysis 2026
Based on fundamental analysis, Bolt Biotherapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bolt Biotherapeutics, Inc. Balance Sheet: BOLT Debt, Cash & Liquidity
BOLT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bolt Biotherapeutics, Inc.'s revenue has grown significantly by 511% over the 5-year period, indicating strong business expansion. The most recent EPS of $-33.06 indicates the company is currently unprofitable.
BOLT Revenue Growth, EPS Growth & YoY Performance
BOLT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $26.0K | -$7.2M | $-4.31 |
| Q3 2025 | $1.1M | -$7.1M | $-3.72 |
| Q2 2025 | $1.3M | -$8.6M | $-4.46 |
| Q1 2025 | $1.2M | -$10.8M | $-0.28 |
| Q3 2024 | $1.1M | -$15.2M | $-0.40 |
| Q2 2024 | $1.3M | -$18.1M | $-0.48 |
| Q1 2024 | $1.8M | -$10.8M | $-0.28 |
| Q3 2023 | $2.1M | -$16.3M | $-0.43 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bolt Biotherapeutics, Inc. Dividends, Buybacks & Capital Allocation
BOLT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bolt Biotherapeutics, Inc. (CIK: 0001641281)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BOLT
What is the AI rating for BOLT?
Bolt Biotherapeutics, Inc. (BOLT) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 89% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BOLT's key strengths?
Claude: Zero debt structure provides financial flexibility and eliminates interest burden. Strong current ratio of 3.51x indicates adequate short-term liquidity to meet obligations. ChatGPT: Debt-free balance sheet reduces financial leverage risk. Current and quick ratios of 3.59x indicate adequate near-term balance sheet liquidity.
What are the risks of investing in BOLT?
Claude: Near-zero revenue of $26K provides no commercial validation or cash generation. Operating cash burn of $8M annually against $11.6M cash reserves creates critical funding timeline. ChatGPT: Operating loss of $36.11M on just $7.70M of revenue reflects an unsustainable cost structure. Free cash flow of -$39.92M versus $11.70M of cash suggests limited runway without additional capital.
What is BOLT's revenue and growth?
Bolt Biotherapeutics, Inc. reported revenue of $26.0K.
Does BOLT pay dividends?
Bolt Biotherapeutics, Inc. does not currently pay dividends.
Where can I find BOLT SEC filings?
Official SEC filings for Bolt Biotherapeutics, Inc. (CIK: 0001641281) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BOLT's EPS?
Bolt Biotherapeutics, Inc. has a diluted EPS of $-4.31.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BOLT's fundamental grade?
Based on our AI fundamental analysis in June 2026, Bolt Biotherapeutics, Inc. has a D grade with 89% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BOLT stock overvalued or undervalued?
Valuation metrics for BOLT: ROE of -36.5% (sector avg: 15%), net margin of -27,861.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BOLT's AI grade for 2026?
Our dual AI analysis gives Bolt Biotherapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BOLT's free cash flow?
Bolt Biotherapeutics, Inc.'s operating cash flow is $-8.0M, with capital expenditures of $72.0K. FCF margin is -31,134.6%.
How does BOLT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -27,861.5% (avg: 12%), ROE -36.5% (avg: 15%), current ratio 3.51 (avg: 2).